Biogen Responds to CMS National Coverage Determination for Monoclonal Antibodies in Alzheimer Disease
Biogen, the developer of aducanumab (Aduhelm) 100-mg/mL injection, a monoclonal antibody (mAb) for the intravenous treatment of Alzheimer disease (AD), has issued a statement in response to the proposed national […]